Skip to main content

Table 5 Tamoxifen versus no tamoxifen and phenotype interaction on Ki-67 modulation.

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

Variable

Reduced

 

Active

 
 

Tamoxifen

Median (Low/upper quartile)

No tamoxifen

Median (Low/upper quartile)

Tamoxifen

Median (Low/upper quartile)

No tamoxifen

Median (Low/upper quartile)

Ki-67 change

2.5 (-2/7)

0 (-5/2)

-2.5 (-10/0)

0 (-1/4)